{"id":"NCT00484939","sponsor":"Hoffmann-La Roche","briefTitle":"A Study of Bevacizumab (Avastin) in Combination With Capecitabine (Xeloda) in Elderly Patients With Metastatic Colorectal Cancer","officialTitle":"A Randomised, Open-label Phase III Study to Assess Efficacy and Safety of Bevacizumab in Combination With Capecitabine as First-line Treatment for Elderly Patients With Metastatic Colorectal Cancer","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-07","primaryCompletion":"2013-03","completion":"2013-03","firstPosted":"2007-06-12","resultsPosted":"2014-06-10","lastUpdate":"2015-01-08"},"enrollment":280,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Colorectal Cancer"],"interventions":[{"type":"DRUG","name":"Bevacizumab","otherNames":["Avastin"]},{"type":"DRUG","name":"Capecitabine","otherNames":["Xeloda"]}],"arms":[{"label":"Bevacizumab + capecitabine","type":"EXPERIMENTAL"},{"label":"Capecitabine","type":"ACTIVE_COMPARATOR"}],"summary":"This 2-arm study assessed the efficacy and safety of bevacizumab (Avastin) in combination with capecitabine (Xeloda), compared with capecitabine alone, in elderly patients with metastatic colorectal cancer. Patients were randomized to receive either bevacizumab (7.5 mg/kg intravenously on Day 1 of each 3-week cycle) in combination with capecitabine (1000 mg/m\\^2 orally twice a day on Days 1-14 of each 3-week cycle) or capecitabine (1000 mg/m\\^2 orally twice a day on Days 1-14 of each 3-week cycle) alone.\n\nNo notable trends or interactions in laboratory values, electrocardiogram, or vital signs suggesting an effect in either direction for capecitabine/bevacizumab combination therapy or capecitabine monotherapy were observed during the study.","primaryOutcome":{"measure":"Progression-free Survival","timeFrame":"Baseline to the end of the study (up to 5 years 8 months)","effectByArm":[{"arm":"Bevacizumab + Capecitabine","deltaMin":9.1,"sd":null},{"arm":"Capecitabine","deltaMin":5.1,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"70 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":5},"locations":{"siteCount":55,"countries":["Austria","Canada","Greece","Hungary","Italy","Mexico","Netherlands","Poland","Slovenia","South Korea","Spain","United Kingdom"]},"refs":{"pmids":["24028813"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":40,"n":134},"commonTop":["Palmar-Plantar erythrodysaesthesia syndrome","Diarrhoea","Nausea","Fatigue","Decreased Appetite"]}}